A Phase II Study of Irinotecan and Etoposide as Treatment for Refractory Metastatic Breast Cancer

LESSONS LEARNED. The combination of irinotecan and etoposide showed modest efficacy in terms of response rate in the refractory setting for patients with metastatic breast cancer. The studied dose and schedule of irinotecan and etoposide is very toxic, with >70% grade 3 or 4 treatment‐related adv...

Descripción completa

Detalles Bibliográficos
Autores principales: Segar, Jennifer M., Reed, Darien, Stopeck, Alison, Livingston, Robert B., Chalasani, Pavani
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2019
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6975935/
https://www.ncbi.nlm.nih.gov/pubmed/31383812
http://dx.doi.org/10.1634/theoncologist.2019-0516

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6975935/
https://www.ncbi.nlm.nih.gov/pubmed/31383812
http://dx.doi.org/10.1634/theoncologist.2019-0516

Ejemplares similares